Mannitol Fresenius Kabi (Mannitol)

Mannitol increases the osmolarity of the extracellular fluid after intravenous administration. This creates an osmotic gradient that draws water out of cells and interstitial spaces into the vascular compartment, leading to increased urine output and a decrease in fluid volume within the brain and eye.

The dose of Mannitol Fresenius Kabi is determined by the prescribing clinician based on the specific indication, patient weight, renal function and clinical response. Healthcare professionals set the infusion rate and total amount according to established medical guidelines.

Mannitol is classified as Pregnancy Category C, meaning risk to the fetus cannot be ruled out. It should only be used when the potential maternal benefit justifies the potential fetal risk. Limited data are available for breastfeeding, so a risk‑benefit assessment is required.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Mannitol is a widely used osmotic diuretic that rapidly increases plasma osmolarity, whereas hypertonic saline achieves a similar effect with a higher sodium load. Mannitol’s renal clearance makes dose adjustment easier in patients with fluctuating kidney function, while hypertonic saline may be preferred when sodium balance is a primary concern.

Mannitol Fresenius Kabi should be stored at 2‑8 °C in a refrigerator. Keep the solution in its original container, protect it from light, and avoid freezing or shaking the vial. Do not use the product if it appears discolored or contains particles.

Mannitol is given as an intravenous infusion. The solution is typically diluted with compatible IV fluids and administered over a period defined by the prescriber, often ranging from a few minutes to several hours, depending on the clinical indication and patient tolerance.

Serious risks include worsening renal failure, severe electrolyte disturbances (especially hyponatremia or hypernatremia), pulmonary edema from rapid fluid shifts, and rare anaphylactic reactions. Patients should be closely monitored for changes in renal function, fluid balance and vital signs during treatment.

Mannitol is contraindicated in patients with severe dehydration, active intracranial bleeding, uncontrolled heart failure, severe pulmonary edema, or known hypersensitivity to Mannitol or any component of the formulation. Caution is also advised in individuals with existing renal impairment.